You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
B-HT 933 dihydrochloride
Biological Activity for B-HT 933 dihydrochloride
B-HT 933 dihydrochloride is a selective α2-adrenoceptor agonist. Exhibits greater than 300-fold selectivity for the α2-adrenoceptor over the α1-adrenoceptor.
Compound Libraries for B-HT 933 dihydrochloride
Technical Data for B-HT 933 dihydrochloride
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for B-HT 933 dihydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for B-HT 933 dihydrochloride
The following data is based on the product molecular weight 254.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.93 mL||19.67 mL||39.35 mL|
|5 mM||0.79 mL||3.93 mL||7.87 mL|
|10 mM||0.39 mL||1.97 mL||3.93 mL|
|50 mM||0.08 mL||0.39 mL||0.79 mL|
Product Datasheets for B-HT 933 dihydrochloride
References for B-HT 933 dihydrochloride
References are publications that support the biological activity of the product.
Bill et al (1989) The thermogenic actions of α2-adrenoceptor agonists in reserpinized mice are mediated via a central postsynaptic α2-adrenoceptor mechanism. Br.J.Pharmacol. 96 133 PMID: 2564288
Parkinson and Hughes (1995) The mechanism of action of α2-adrenoceptors in human isolated subcutaneous resistance arteries. Br.J.Pharmacol. 115 1463 PMID: 8564206
Kobinger and Pichler (1977) Pharmacological characterization of B-HT 933 (2-amino-6-ethyl-4,5,7,8-tetrahydro-6H-oxazolo-[5,4-d]-azepindihydrochloride) as a hypotensive agent of the "clonidine-type". Naunyn-Schmied.Arch.Pharmacol. 300 39 PMID: 22821
If you know of a relevant reference for B-HT 933 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: B-HT 933 dihydrochloride, B-HT 933 dihydrochloride supplier, B-HT933, dihydrochloride, azepexole, alpha2, α2, a2, adrenoceptors, agonists, selective, adrenergic, receptors, Azepexole, Adrenergic, Alpha-2, Receptors, 2758, Tocris Bioscience
1 Citation for B-HT 933 dihydrochloride
Citations are publications that use Tocris products. Selected citations for B-HT 933 dihydrochloride include:
Hamby et al (2012) Inflammatory mediators alter the astrocyte transcriptome and calcium signaling elicited by multiple G-protein-coupled receptors. Toxins (Basel) 32 14489 PMID: 23077035
Do you know of a great paper that uses B-HT 933 dihydrochloride from Tocris? Please let us know.
Reviews for B-HT 933 dihydrochloride
There are currently no reviews for this product. Be the first to review B-HT 933 dihydrochloride and earn rewards!
Have you used B-HT 933 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.